上實城市開發(00563.HK)擬建立合營 在中國上海開發醫療美容機構
格隆匯 10 月 30日丨上實城市開發(00563.HK)公告，公司全資附屬公司上實城開上海大健康管理擬參與合組合營企業，據此，合營企業將於中國上海市開發及經營醫療美容機構。合營企業合夥人將委聘上海第九人民醫院提供管理服務。
合營企業合夥人(包括上實城開上海大健康管理)就此於2020年10月30日與上海第九人民醫院訂立管理協議。為進行該項目，合營企業合夥人將成立合營企業並採納合營企業章程細則為其憲章文件。在合營企業成立時，合營企業將由上海凌風醫療、上海華氏及上實城開上海大健康管理分別擁有51%、30%及19%。
公司為根據百慕達法律註冊成立有限公司及為投資控股公司。集團為中國物業開發商，主要在中國從事物業開發、物業投資及酒店經營業務。上海凌風醫療為於中國成立有限責任公司及上實集團全資附屬公司，主要從事醫院管理，以及提供企業管理諮詢及信息諮詢服務。
上海華氏為於中國成立有限責任公司及上海醫藥(集團)全資附屬公司，主要從事房地產開發及投資、實業投資、資產管理、經濟信息諮詢、醫藥技術開發、財務顧問，以及其他相關科技及財務服務。
集團認為，合組合營企業在上海市開發及經營醫療美容機構，可為集團締造良機進軍大健康產業，把握長遠戰略發展機遇。上海第九人民醫院為中國具有市場領導地位三級甲等公立醫院，在醫療領域具備全國頂尖綜合實力。通過委聘上海第九人民醫院提供管理服務，集團便可利用上海第九人民醫院豐富經驗及知識獲益。
長遠而言，公司相信，大健康產業戰略發展將可進一步拓展集團收入來源，而進軍此新業態產業亦有助提高股東回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
